Smart-ring company Oura is seeking to raise up to $2.2 billion through an initial public offering, according to a filing submitted to the relevant authorities on Monday. The company has not yet set the final offering price, but estimated the share price at between $40 and $44. It plans to offer 13.5 million new shares, while existing shareholders will sell 36.5 million shares, for a total of 50 million shares.
Oura plans to trade on the Nasdaq under the ticker OURA. Its business is based on selling smart rings and related subscriptions, while the offering filing points to revenue growth from both sources.
What Makes the Offering Stand Out?
The IPO comes amid a broader shift in the wearable-device market, as companies seek to add health functions beyond activity, sleep, and stress tracking. Oura currently provides measurements and indicators related to these areas, along with the ability to upload blood-test results. It has also entered into partnerships with Dexcom, which specializes in continuous glucose-monitoring devices, and ResMed, which makes devices for treating sleep apnea and other respiratory conditions.
But expanding health functions puts the company on a boundary between wellness tools and regulated medical devices. According to the filing, none of Oura’s current functions has received authorization from the U.S. Food and Drug Administration (FDA) as a medical device, because they fall under the wellness-product exemption.
Regulatory Boundaries and the Legal Case
Oura says it plans to provide a tool that tracks nighttime blood-pressure trends, a function the FDA considers a wellness function. At the same time, the company is studying a feature intended to detect risks of undiagnosed high blood pressure; this feature would need to go through the regulator if it became a medical product subject to evaluation.
The company warned in its offering filing that there is no guarantee the FDA will consider its functions exempt from medical-device regulation. It noted that general wellness guidance could change in the future and narrow the scope of products the agency can address under its regulatory discretion. Earlier this year, the FDA amended the guidance without prior announcement, allowing some wearable devices that measure blood pressure to benefit from the wellness exemption if they meet specific conditions.
Oura also faces a proposed class-action lawsuit concerning the accuracy of its sleep-tracking functions, a legal factor that adds to the risks investors must assess before the offering.
Why Does This News Matter?
The offering represents a test for the consumer health-device market as much as it represents a financing step for Oura. The company’s success depends on a model that combines hardware and subscriptions, but it also requires careful management of health claims and the boundaries of the regulatory exemption. The filing has not yet settled the final IPO price or the offering’s outcome, and the regulatory status of future features will remain tied to the FDA’s interpretation and changing guidance.